Bispecific Antibodies to Target Latent HIV-1 Infection


The invention describes bispecific antibodies designed to kill latently HIV-1 infected T cells. It is thought that such bispecific antibodies will reduce or eliminate the pool of HIV-1 infected cells, contributing to functional cure. The antibody constructs comprise an HIV Env-binding fragment of a broadly neutralizing antibody linked to an anti-CD3 single chain variable fragment (scFv). One embodiment is a VRC01 scFv linked to the anti-CD3 scFv . Other embodiments comprise Fab fragments of VRC07 or 10E8 antibodies linked to the anti-CD3 scFv. The bispecific antibody simultaneously stimulates infected cells to express gp120, instructs cytotoxic T cells to kill these cells, and neutralizes extraneous viral particles.

Potential Commercial Applications: Competitive Advantages:
  • Immunotherapy of HAART-suppressed HIV-1 infection.
 
  • Immunotherapy targets latently infected cells harboring virus resistant to HAART.
  • Broadly neutralizing antibody fragment neutralizes extraneous viral particles.


Related Invention(s):



Inventors:
Gary Nabel (NIAID)
Zhi-yong Yang (NIAID)
Amarenda Pegu (NIAID)
Xiaoti Guo (NIAID)


Intellectual Property:
US Application No. 61/638,437
PCT Application No. PCT/US2013/038214


Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases, Vaccine Research Center, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize HIV-1 bispecific antibodies. For collaboration opportunities, please contact Barry Buchbinder, Ph.D. at 301-594-1696.


Licensing Contact:
Cristina Thalhammer-Reyero , Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 33
Rockville , MD 20852
Email: thalhamc@mail.nih.gov
Phone: 301-435-4507
Fax: 301-402-0220

OTT Reference No: E-071-2012/0

Updated: 01/06/2014